Results 111 to 120 of about 1,795 (145)
Australian prescriberSome of the next articles are maybe not open access.
Related searches:
Related searches:
The role of emicizumab in acquired hemophilia A
Hematology, 2023Abstract Acquired hemophilia is a rare bleeding disorder that predominantly affects older people with potential underlying comorbidities, including cardiovascular and thrombotic risk factors. The current standard therapies with hemostatic agents for acute bleeding and immunosuppression often require inpatient management, are not approved
Jacqueline, Poston +1 more
openaire +2 more sources
Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement
Pathology, 2022Emicizumab is a recombinant, humanised bispecific antibody which acts as a FVIII mimetic and is a therapeutic option for haemophilia A. Plasma emicizumab levels may sometimes be required. Multiple one-stage clotting assays (OSA) and one human component chromogenic assay (CSA) were used to measure emicizumab both centrally and by a field study.
Geoffrey Kershaw +4 more
openaire +2 more sources
Emicizumab for the treatment of acquired hemophilia A
Blood, 2021Abstract Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents and human or porcine FVIII are currently standard of care.
Paul Knoebl +5 more
openaire +2 more sources